ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

3:30PM-3:45PM: Abstract Number: 0845

Machine Learning–Based Skin Transcriptome Classifier (v2.0) Links SSc Molecular Subtypes to Disease Severity and Progression

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I (0843–0848)

3:30PM-3:45PM: Abstract Number: 0815

Neuropathic-like Pain Characteristics Predict Worse Pain Outcomes in Early Rheumatoid Arthritis: a Prospective Cohort Study with Embedded Neuroimaging Evaluation

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia (0813–0818)

3:30PM-3:45PM: Abstract Number: 0839

Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis (0837–0842)

3:30PM-3:45PM: Abstract Number: 0833

Sputum Anti-CCP-IgA and NET-Associated Proteins Predict Risk and Timing of the Transition From Systemic Autoimmunity to Classified RA

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes II: Look What You Made Me Do (Prediction) (0831–0836)

3:30PM-3:45PM: Abstract Number: 0827

Utilization of American College of Rheumatology Vaccination Guidelines in Clinic: A Needs Assessment in an Internal Medicine Residency Program

Abstracts: Professional Education (0825–0830)

3:45PM-4:00PM: Abstract Number: 0846

A Longitudinal Transcriptomic Study of Mycophenolate Mofetil in Systemic Sclerosis Skin with Clinical and Molecular Stratification

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I (0843–0848)

3:45PM-4:00PM: Abstract Number: 0822

Clinical and Mechanistic Insight of Circulating Calprotectin and NXP2 autoantibodies in Juvenile Dermatomyositis

Abstracts: Pediatric Rheumatology – Basic Science (0819–0824)

3:45PM-4:00PM: Abstract Number: 0834

Heterogeneity in the Association of Genetic Risk for Rheumatoid Arthritis and Resultant Rheumatoid Arthritis Phenotypes

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes II: Look What You Made Me Do (Prediction) (0831–0836)

3:45PM-4:00PM: Abstract Number: 0816

Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia (0813–0818)

3:45PM-4:00PM: Abstract Number: 0840

Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis (0837–0842)

3:45PM-4:00PM: Abstract Number: 0828

Two Common AI Models Create Poor Rheumatology Board Style Questions

Abstracts: Professional Education (0825–0830)

4:00PM-4:15PM: Abstract Number: 0841

Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes I: Advances in Nephritis (0837–0842)

4:00PM-4:15PM: Abstract Number: 0835

IgG Glycome In Early Rheumatoid Arthritis Differs From Matched Controls and Links Less Lean Mass to an Early Aging Phenotype

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes II: Look What You Made Me Do (Prediction) (0831–0836)

4:00PM-4:15PM: Abstract Number: 0847

Interferon Score Effectively Stratifies for Time to Clinically Significant Event Accrual in Systemic Sclerosis Independently of Cutaneous Subset

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I (0843–0848)

4:00PM-4:15PM: Abstract Number: 0823

Longitudinal model of paired peripheral blood CITE-seq and skin scRNA-seq data in juvenile systemic sclerosis (jSSc) patients following autologous stem cell transplant (ASCT) reveals reduced expression of SSc marker genes

Abstracts: Pediatric Rheumatology – Basic Science (0819–0824)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].